BioDelivery Sciences International, Inc. (BDSI): Price and Financial Metrics


BioDelivery Sciences International, Inc. (BDSI): $3.66

0.00 (0.00%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

Add BDSI to Watchlist
Sign Up

Industry: Biotech


Ranked

of 455

in industry

BDSI POWR Grades


  • BDSI scores best on the Quality dimension, with a Quality rank ahead of 97.23% of US stocks.
  • BDSI's strongest trending metric is Growth; it's been moving down over the last 169 days.
  • BDSI's current lowest rank is in the Growth metric (where it is better than 11.31% of US stocks).

BDSI Stock Summary

  • Of note is the ratio of Biodelivery Sciences International Inc's sales and general administrative expense to its total operating expenses; 85.9% of US stocks have a lower such ratio.
  • With a year-over-year growth in debt of -25.07%, Biodelivery Sciences International Inc's debt growth rate surpasses only 18.75% of about US stocks.
  • Shareholder yield, a measure of how much is returned to shareholders via dividends and share repurchases, for BDSI comes in at 8.54% -- higher than that of 78.76% of stocks in our set.
  • If you're looking for stocks that are quantitatively similar to Biodelivery Sciences International Inc, a group of peers worth examining would be MHH, PETS, ZDGE, III, and WGO.
  • Visit BDSI's SEC page to see the company's official filings. To visit the company's web site, go to www.bdsi.com.

BDSI Valuation Summary

  • BDSI's price/earnings ratio is 11.2; this is 69.32% lower than that of the median Healthcare stock.
  • Over the past 233 months, BDSI's price/earnings ratio has gone up 13.8.
  • Over the past 233 months, BDSI's price/sales ratio has gone down 18.6.

Below are key valuation metrics over time for BDSI.

Stock Date P/S P/B P/E EV/EBIT
BDSI 2021-08-31 2.3 3.3 11.2 7.9
BDSI 2021-08-30 2.3 3.3 11.0 7.7
BDSI 2021-08-27 2.3 3.3 11.1 7.8
BDSI 2021-08-26 2.3 3.3 11.2 7.9
BDSI 2021-08-25 2.2 3.2 10.9 7.6
BDSI 2021-08-24 2.3 3.3 10.9 7.7

BDSI Growth Metrics

    The 2 year net cashflow from operations growth rate now stands at 167.35%.
  • Its year over year revenue growth rate is now at 22.57%.
  • The 2 year cash and equivalents growth rate now stands at 484.06%.
Over the past 49 months, BDSI's revenue has gone up $112,312,000.

The table below shows BDSI's growth in key financial areas (numbers in millions of US dollars).

Date Revenue Operating Cash Flow Net Income to Common Stock
2021-09-30 165.718 38.305 31.166
2021-06-30 164.069 40.319 33.88
2021-03-31 159.212 29.691 25.981
2020-12-31 156.471 24.981 25.711
2020-09-30 145.94 30.886 14.818
2020-06-30 136.803 20.435 5.789

BDSI's Quality Factors

The “Quality” component of the POWR Ratings focuses on 31 different factors of a companies fundamentals and operational strength. Here are some key insights as we drill into the specifics of these quality attributes.
  • BDSI has a Quality Grade of A, ranking ahead of 98.15% of graded US stocks.
  • BDSI's asset turnover comes in at 0.683 -- ranking 43rd of 681 Pharmaceutical Products stocks.
  • INSM, CYRX, and CTLT are the stocks whose asset turnover ratios are most correlated with BDSI.

The table below shows BDSI's key quality metrics over time.

Period Asset Turnover Gross Margin ROIC
2021-06-30 0.683 0.855 0.451
2021-03-31 0.685 0.843 0.363
2020-12-31 0.708 0.842 0.381
2020-09-30 0.705 0.838 0.274
2020-06-30 0.708 0.827 0.160
2020-03-31 0.722 0.822 0.178

BDSI Price Target

For more insight on analysts targets of BDSI, see our BDSI price target page. And for a list of of all stocks sorted by upside potential based on analyst target price, see our Top Price Target page.

Average Price Target $6.88 Average Broker Recommendation 1.44 (Moderate Buy)

BDSI Stock Price Chart Interactive Chart >

Price chart for BDSI

BDSI Price/Volume Stats

Current price $3.66 52-week high $4.68
Prev. close $3.66 52-week low $2.50
Day low $3.56 Volume 1,056,079
Day high $3.67 Avg. volume 1,468,555
50-day MA $3.03 Dividend yield N/A
200-day MA $3.53 Market Cap 361.59M

BioDelivery Sciences International, Inc. (BDSI) Company Bio


BioDelivery Sciences International, Inc. engages in the development and commercialization of pharmaceutical products principally in the areas of pain management and addiction. The company was founded in 1997 and is based in Raleigh, North Carolina.


BDSI Latest News Stream


Event/Time News Detail
Loading, please wait...

BDSI Latest Social Stream


Loading social stream, please wait...

View Full BDSI Social Stream

Latest BDSI News From Around the Web

Below are the latest news stories about Biodelivery Sciences International Inc that investors may wish to consider to help them evaluate BDSI as an investment opportunity.

Why Shares of BioDelivery Sciences International Jumped 12.2% on Monday

Shares of the small pharmaceutical company, which focuses on pain management, have been rising since it released updated guidance late last week.

Yahoo | January 24, 2022

Analysts Offer Insights on Healthcare Companies: BioDelivery (BDSI), Aslan Pharmaceuticals (ASLN) and Compass Therapeutics (CMPX)

Analysts have been eager to weigh in on the Healthcare sector with new ratings on BioDelivery (BDSI – Research Report), Aslan Pharmaceuticals (ASLN – Research Report) and Compass Therapeutics (CMPX – Research Report). BioDelivery (BDSI) H.C. Wainwright analyst Oren Livnat maintained a Hold rating on BioDelivery today and set a price target of $4.50. The company's shares closed last Thursday at $3.18. According to TipRanks.

Christine Brown on TipRanks | January 21, 2022

BioDelivery (BDSI) Stock Up on Raised Guidance for 2021

BioDelivery Sciences International (BDSI) raises its financial guidance for full-year 2021. BDSI expects sales at the high end of its previous guidance.

Yahoo | January 21, 2022

BioDelivery Sciences Expects 2021 Revenue at the High End of Full Year Guidance

Total 2021 Net Revenue expected in the range of $165 -$167 million, as compared to previous guidance of $162-$167 million BELBUCA 2021 Net Sales expected to be in the range of $147 -$148 million, as compared to previous guidance of $144-$148 million 2021 EBITDA expected to be in the $40 - $45 million range as compared with previous guidance of <$40 million RALEIGH, N.C., Jan. 20, 2022 (GLOBE NEWSWIRE) -- BioDelivery Sciences International, Inc. (NASDAQ: BDSI), a growing specialty pharmaceutical

Yahoo | January 20, 2022

BioDelivery Sciences International, Inc. (NASDAQ:BDSI) insiders placed bullish bets worth US$807k in the last 12 months

Generally, when a single insider buys stock, it is usually not a big deal. However, when several insiders are buying...

Yahoo | January 1, 2022

Read More 'BDSI' Stories Here

BDSI Price Returns

1-mo 18.06%
3-mo -10.29%
6-mo -2.66%
1-year -6.39%
3-year -17.94%
5-year 87.69%
YTD 18.06%
2021 -26.19%
2020 -33.54%
2019 70.81%
2018 25.42%
2017 68.57%

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!


Page generated in 0.8005 seconds.